Inhalable songorine-integrated lipid nanomedicine for targeted ARDS therapy via repairing endothelial barrier and inactivating NLRP3 inflammasome.

In a lipopolysaccharide-induced ARDS mouse model, the authors demonstrated that Son-lipo effectively targeted inflamed lung tissues with commendable biocompatibility. It elucidates the formulation's ability to mitigate ARDS by repairing the endothelial barrier and reversing the inflammatory microenvironment, thereby providing a promising candidate drug for improving clinical management of ARDS.

A Countstar instrument measured cell numbers in cell suspensions during quality assessment in the 2026 Acta pharmaceutica Sinica. B study.